Standard BioTools, Navignostics announce collaboration agreement

Standard BioTools announced a collaboration agreement with Navignostics AG for development of clinical research applications and service offerings using the Hyperion XTi Imaging System. “We are very excited about this collaboration. Characterizing tumors using spatial single-cell proteomics enables identification of optimal treatments for an individual patient’s tumor and helps accelerate drug development by providing key insights into drug mechanisms and tumor features. Our ability to automate and standardize this process with IMC has really pushed us to where we are now, bringing novel developments into the clinical space to help inform treatment decisions for cancer patients,” said Jana Fischer, Chief Executive Officer of Navignostics. As part of the agreement, Standard BioTools will support the development of Navignostics assays by collaborating on various aspects of protocols and instrument and software features. Additionally, both Navignostics and Standard BioTools plan to leverage their learnings to advance the science of IMC by co-publishing and presenting at scientific conferences in the coming year.